MedTrace Logo

Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression

NCT03800576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2021-03-16

No results posted yet for this study

Summary

Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting therapeutic outcome and individualized dosage remains to be a challenge. The study's objective is to identify the genetic and clinical factors that can influence clinical outcome in liver transplant.

Conditions

  • Liver Transplantation

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Rey-Heng Hu, Professor · National Taiwan University Hospital

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-06
Primary Completion
2019-10-08
Completion
2020-09-22

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03800576 on ClinicalTrials.gov